Advanced search
Start date
Betweenand

Metastasis inhibition via epithelial-mesenchymal transition by metformin in mammary neoplasia

Grant number: 12/25146-5
Support type:Scholarships abroad - Research Internship - Doctorate
Effective date (Start): March 16, 2013
Effective date (End): August 15, 2013
Field of knowledge:Agronomical Sciences - Veterinary Medicine - Animal Pathology
Principal researcher:Debora Aparecida Pires de Campos Zuccari
Grantee:Camila Leonel da Silva
Supervisor abroad: Alicia Mercedes Viloria-Petit
Home Institution: Faculdade de Medicina de São José do Rio Preto (FAMERP). Secretaria de Desenvolvimento Econômico (São Paulo - Estado). São José do Rio Preto , SP, Brazil
Research place: University of Guelph, Canada  
Associated to the scholarship:12/09778-1 - METASTASIS INHIBITION VIA EPITHELIAL-MESENCHYMAL TRANSITION BY RNA INTERFERENCE AND METFORMIN IN MAMMARY NEOPLASIA, BP.DR

Abstract

The Epithelial-mesenchymal transition (EMT) is characterized by the change in mesenchymal to epithelial phenotype leads to loss or reduced expression of markers of epithelial cells such as E-cadherin and claudin, and increased expression of markers of mesenchymal cells such as n- cadherin and vimentin, as well as increased expression of the transcription factor twist. The EMT can be induced by extracellular matrix components and growth factors such as transforming growth factor beta (TGF-²), responsible for regulating cellular differentiation and proliferation, migration and apoptosis. The EMT starts with the transformation and differentiation of stem cells in breast cancer (BCSCs). Recent studies reproduced in vitro process of EMT in mammary epithelial cells generating cell BCSCs properties. In addition, a small subpopulation of tumor cells with the phenotype characteristic of stem cells (CD44 + / CD24-) are present in breast tumors. Currently, various tools of intervention have been employed to inhibit EMT and subsequent metastasis, for this purpose, recently emerged new research using metformin, a drug for type 2 diabetes, inhibiting the action of TGF-B in EMT and subsequent metastasis of breast cancer. The objective of this study is to identify markers associated with EMT, by immunofluorescence staining and RT-PCR, and prevent the process of metastasis of breast cancer through inhibition of TGF-² by treatment with metformin in canine breast cancer cell lines. The data obtained in this study will confirm the likely benefits of metformin as therapeutic agent in the treatment of breast cancer, reducing the occurrence of metastases and thus contributing to a better prognosis for patients with breast cancer. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Please report errors in scientific publications list by writing to: cdi@fapesp.br.